Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis

Chen, Nan; Hao, Chuan‐Ming; Liu, Bi‐Cheng; Lin, Hongli; Wang, Caili; Xing, Changying; Liang, Xinling; Jiang, Gengru; Liu, Zhengrong; Li, Xuemei; Zuo, Li; Luo, Laimin; Wang, Jianqin; Zhao, Minghui; Liu, Zhihong; Cai, Guangyan; Li, Hao; Leong, Robert; Wang, Chunrong; Liu, Cameron; B. Neff, Thomas; A. Szczech, Lynda; P. Yu, Kin-Hung

doi:10.1056/nejmoa1901713

Public

Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis

Published in New England Journal of Medicine • Jul 24, 2019

Authors:

Nan Chen

Chuan‐Ming Hao

Bi‐Cheng Liu

Abstract

BACKGROUND: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Additional data are needed regarding the effectiveness and safety of roxadustat as compared with standard therapy (epoetin alfa) for the treatment of ...

Subject

Anemia

Medicine

Erythropoiesis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!